Volex has acquired the remaining 64.3% of Kepler SignalTek in a transaction worth up to $89.4 million, taking full ownership of a manufacturer specialising in patient-connected medical cables and devices.
Signing and completion occurred together on 14 July, bringing the business into Volex’s medical division as a fully consolidated subsidiary. Volex had held a 35.7% interest since Kepler SignalTek was established in 2017.
The consideration includes an initial cash payment of approximately $74.7 million, subject to net debt and working capital adjustments, together with deferred payments of up to $14.7 million. The later tranches depend on revenue targets being achieved during the two years following completion.
Kepler SignalTek manufactures single-use and reusable products for patient monitoring, surgery, cardiac therapy, and ultrasound imaging. Production is undertaken at facilities in Dongguan, China, and Batam, Indonesia, where the company supplies healthcare technology customers requiring controlled processes and regulated product traceability.
Revenue reached $51.8 million in the year to 31 March 2026, following organic growth of 10%. Volex expects the acquisition to improve earnings immediately and has set a target for return on capital employed to exceed 15% within two years.
Volex’s existing medical business concentrates largely on power and data assemblies installed within equipment such as magnetic resonance imaging systems, robotic surgery platforms, and diagnostic imaging machines. Kepler SignalTek extends the group’s position to products that connect the equipment directly with the patient.
Nat Rothschild, chief executive officer of Volex, said: “The Acquisition extends Volex from manufacturing the cables and assemblies inside medical equipment to supplying the products that connect that equipment to the patient, with limited customer overlap and clear scope to grow together.”
Patient-connected products occupy a demanding position within the device architecture. They must preserve electrical or acoustic performance while tolerating movement, repeated connection, cleaning, disinfection, mechanical loading, and contact with clinical environments.
Reusable products require evidence that materials, insulation, strain relief, connectors, and markings will survive the specified number of cycles without degrading beyond acceptable limits. Single-use products introduce different pressures around production volume, contamination control, packaging integrity, sterilisation compatibility, and disposal.
Manufacturing controls extend from incoming conductor, polymer, sensor, and connector materials through assembly, moulding, soldering, testing, packaging, and final release. Where a product carries a signal used for diagnosis or therapy, intermittent connections and electrical noise can affect more than equipment convenience.
Traceability must allow each released batch or serialised product to be linked with its materials, process conditions, test results, operators, and approved work instructions. Changes to tooling, suppliers, production sites, or software-controlled test equipment may require formal review and, in some cases, customer or regulatory approval.
Volex expects limited overlap between the companies’ customer bases, creating an opportunity to offer Kepler SignalTek products to established medical equipment manufacturers. Kepler SignalTek can, in turn, provide access to programmes where Volex’s internal power and data assemblies may complement the patient interface.
Medical equipment companies have been reducing the number of manufacturing interfaces they manage while retaining specialist suppliers for technically sensitive components. A partner capable of producing internal cables, power assemblies, electromechanical systems, and patient-connected devices can assume greater responsibility for procurement and industrialisation.
The expansion of certified medical electronics capacity, including ESCATEC’s ISO 13485-certified UK operation, reflects growing demand for suppliers able to combine electronics manufacturing with controlled quality systems and documented risk management.
Consolidation does not simplify the underlying regulatory work. Product registrations, validated processes, customer approvals, design histories, and supplier controls remain attached to specific products and facilities. Volex must integrate commercial, financial, and purchasing systems without disrupting the manufacturing discipline on which those approvals depend.
Scott Hayden, who founded Kepler SignalTek, will continue to lead the company with its existing management team. Retaining that operational knowledge should reduce integration risk, particularly where customer relationships depend on detailed product history and direct engineering support.
The acquisition will be funded through Volex’s existing debt facilities, with pro forma covenant leverage expected to remain at approximately 1.1 times. The deferred consideration structure links part of the purchase price to continued commercial performance after ownership changes.
Full control gives Volex greater authority over capital investment, capacity, product development, and customer strategy. It can also align procurement and manufacturing across a global network, provided that any transfer of components or processes is validated before implementation.
The wider medical technology market continues to combine growing demand with pressure on cost, lead time, and regulatory compliance. Device manufacturers want more resilient supply arrangements but remain cautious about changes that could trigger requalification or affect clinical performance.
Kepler SignalTek gives Volex a larger role at the patient interface, where design and manufacturing errors carry higher consequences and where supplier continuity is particularly valuable. The return on the acquisition will depend on expanding that business without weakening the process control that allowed it to grow.
